Canada’s Jamp Pharma has delivered on plans to create a new dedicated biosimilars division as it prepares to launch the recently-approved higher-strength adalimumab biosimilar on which it has partnered with Alvotech.
Canada’s Jamp Pharma is positioning itself to break into the Canadian biosimilars market by creating a dedicated biosimilars division, BioJamp, with a goal of “improving and simplifying the complex world of biosimilars for patients and healthcare professionals.”
BioJamp’s mission “is to offer biosimilar products aimed at improving the experience of patients and healthcare professionals, at a considerably...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
